Drug Discovery Patents: Leaders, Trends & White Space 2026
- 11.5% concentration at the top. The five leading assignees combined hold 17,079 of 148,175 records in scope — a real edge, but far from a closed field.
- Filing has cooled since the 2017 peak of 491. Complete-year data shows a 43% drop from 437 filings in 2021 to 251 in 2024, though 2025-26 figures are still filling in under publication lag.
- Assay and Fc-engineering prior art runs deep. The most-cited record in the set has been cited 1,497 times, meaning binding-domain and Fc-variant claims sit on unusually dense prior art.
Filing growth compares 2021 (437 records) with 2024 (251) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 148,175 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset covers 148,175 published records matching drug screening, lead discovery and drug discovery filings paired with dosage composition, binding assay, therapeutic response, delivery carrier, therapeutic target or therapeutic molecule terms, from 2015 through the 2026-08-31 cut-off. It spans large-molecule discovery infrastructure, small-molecule screening platforms, and the delivery and dosing claims that sit downstream of a validated target. Because a single record can carry several IPC classes, the technology composition below should be read as class-by-class share of the full record count, not as a partition.
Read as patent families, this landscape favours breadth over depth: the leader holds 7,045 records against a fifth-place figure of 2,389 and a tenth-place figure of 1,726, and the top ten combined account for 17.9% of all records in scope. That gap between first place and the rest is the field's most useful signal — a strong lead position, but one surrounded by a long tail of active filers.
Filing trend and technology composition
Two views of the same 148,175-record set: how filing volume has moved year over year, and which IPC subclasses carry the most records.
Filing trend, 2017–2026
Filings peaked in 2017 at 491 and, on the last complete comparison available, fell 43% from 437 in 2021 to 251 in 2024. Treat 2025 and 2026 as undercounted rather than as evidence of a further decline — publication lags filing by roughly 18 months.
Technology composition by IPC subclass
Medicinal preparations (A61K, 7.8% of records) and peptides & proteins (C07K, 7.4%) lead, followed by material analysis and testing (G01N, 6.4%) and microorganism/genetic engineering work (C12N, 6.1%). Enzymatic and nucleic-acid classes (C12Q, A61P, C12P, C07H) each sit below 5%, marking the narrower, more specialised bands of the field.
Shares are the percentage of the 148,175 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Drug Discovery & Screening Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about drug discovery & screening patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this landscape
US20040117125A1 — Drug discovery method and apparatus
Methods and systems for drug discovery and development are disclosed. One or more databases comprising chemical and biological interaction data, paired with computer-based data analysis programs, are used to identify compounds active at two or more molecular targets associated with a disease state, or compounds with defined selectivity profiles across target panels.Filed by Novascreen Biosciences; illustrative of the multi-target screening approach that recurs across this landscape.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2004003019A2 | Immunoglobin single variant antigen-binding domains and dual-specific constructs | 1,497 |
| 2 | WO2006019447A1 | Optimized fc variants | 1,231 |
| 3 | US5639603A | Synthesizing and screening molecular diversity | 988 |
| 4 | US20140179770A1 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and the… | 981 |
| 5 | US20060024298A1 | Optimized Fc variants | 836 |
| 6 | US6599692B1 | Functional genomics using zinc finger proteins | 814 |
| 7 | WO2004058821A2 | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand | 779 |
| 8 | US6342219B1 | Antibody compositions for selectively inhibiting VEGF | 778 |
| 9 | WO2004041867A2 | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders | 767 |
| 10 | US20140242699A1 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and the… | 727 |
Citation counts inside a searched corpus favour older filings; treat them as a measure of influence on later claims, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three findings that change where a search or freedom-to-operate review should start.
A real lead, not a monopoly
The top five assignees combined hold 17,079 records, 11.5% of the full record set, and the top ten reach 17.9%. That leaves the large majority of filings spread across a long tail of single- and few-filing entrants, which is where freedom-to-operate risk is more fragmented than concentrated.
Volume has pulled back from its peak
Filings peaked at 491 in 2017 and, over the last fully comparable window, dropped from 437 in 2021 to 251 in 2024. That is a real cooling, but the two most recent years in the dataset are still under-reported because publication trails filing by about 18 months.
Binding-domain and Fc claims are heavily built on
The most-cited record in this set, on single-variant antigen-binding domains and dual-specific constructs, carries 1,497 citations; a second Fc-variant record carries 1,231. New filings that touch antibody engineering or Fc optimisation are landing on some of the densest prior art in the whole landscape.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to drug discovery & screening patent landscape, with the prior art for and against each one.
Who is filing, and where the collaboration ties sit
The ranking covers 100 companies counted in records — the full set the data endpoint returns, not a curated top list. Beneath the leader group, filing activity spreads thin.
A clear single leader
The top-ranked assignee holds 7,045 records, well ahead of the fifth-place figure of 2,389 and the tenth-place figure of 1,726 — a steep drop-off that marks a genuine leadership position rather than a crowded tie at the top.
A small set of tight co-assignee pairs
Only 10 co-assignee pairs appear in this dataset, and the strongest pairing shares 714 records, with two related pairings close behind at 680 and 677. Collaboration in this field looks like a handful of durable individual-to-corporate ties rather than a broad partnering network.
Latest-year filings have gone quiet across leaders
Recent-year momentum among the named leading assignees and inventors sits at zero to two records each in the latest year. Given the 18-month publication lag, this understates real activity, but it also means the latest-year picture should not be read as a ranking change in itself.
| Assignee | Recent year | YoY |
|---|---|---|
| Genentech | 2 | — |
| Human Genome Sciences | 0 | — |
| Bayer HealthCare AG | 0 | — |
| GOLZ STEFAN | 0 | — |
| BRUGGEMEIER ULF | 0 | — |
| Incyte Corporation | 0 | — |
| GEERTS ANDREAS | 0 | — |
| RUBEN STEVEN M | 0 | — |
Where to take this next
The landscape points to three practical follow-ups depending on what you're trying to decide.
Run a freedom-to-operate check on Fc and binding-domain claims
With the two most-cited records in this set both concentrated on antibody binding domains and Fc variants, any new antibody-engineering filing should be checked against this prior art before drafting claims.
Explore Fc and binding-domain prior art →Track the under-claimed branches before they fill in
Fermentation-route synthesis and nucleic-acid sugar chemistry carry noticeably fewer records than the core screening and assay classes, which is where a first claim still has room to stand.
Map white space in these branches →Watch the long tail, not just the leader
With 88.5% of records sitting outside the top five assignees, competitive monitoring needs to cover the fragmented tail as closely as the named leader.
Set up assignee monitoring →Common questions about this landscape
The ranking in this dataset covers 100 companies, with the leading assignee holding 7,045 records against a fifth-place figure of 2,389 and a tenth-place figure of 1,726. That gap shows one organisation with a clear lead rather than several tied at the top. Even so, the top five combined account for only 11.5% of the 148,175 records in scope, so the majority of filing activity sits with a long tail of smaller and single-filing entrants rather than a concentrated group.
Filings peaked in 2017 at 491 and, over the most recent fully comparable window, fell 43% from 437 in 2021 to 251 in 2024. That is a genuine pullback in complete-year terms. However, the 2025 and 2026 figures in any raw trend chart will look much lower still, because publication lags filing by roughly 18 months — those years are undercounted, not necessarily lower in true filing volume.
Medicinal preparations (A61K) and peptides and proteins (C07K) are the two largest IPC subclasses, each covering roughly 7.5% of the 148,175 records in scope. Material analysis and testing (G01N) and microorganism or genetic engineering work (C12N) follow close behind. Because a single record can carry multiple IPC codes, these shares add up to more than 100% of the record total and should be read as overlapping footprints, not a strict split of the field.
US20040117125A1, filed by Novascreen Biosciences, describes methods and systems that use databases of chemical and biological interaction data together with computer-based analysis programs to identify compounds active at two or more molecular targets tied to a disease state. It is a multi-target screening and selectivity-profiling approach rather than a claim on any single compound or assay format. Anyone building a computational multi-target screening pipeline should read its claims closely, since the same functional idea recurs across many later filings in this landscape.
The comparatively lower-density IPC classes in this dataset — fermentation and enzymatic synthesis (C12P) and sugar/nucleic-acid chemistry (C07H), each under 3% of records — carry meaningfully less filing volume than the core screening and assay classes. Co-assignee collaboration is also thin: only 10 co-assignee pairs appear across the whole dataset. Both signals point to delivery-carrier co-formulation and cross-target assay panel claims as areas where a well-drafted first claim still has room, rather than landing on top of dense existing art.
Research Drug Discovery & Screening Patent Landscape in depth with Eureka
Go past this page: query the whole drug discovery & screening patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.